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The Author Replies: In their letters to the editor, two groups,
from Los Angeles1 and Saitama, Japan,2 respectively, raised
some concerns regarding the methodology and the results of
our previously published study on renal blood oxygen level–
dependent magnetic resonance imaging (BOLD-MRI) in a
non-selected patient group. The current literature on renal
BOLD-MRI and its applications presents heterogeneous
results regarding the correlation between R2* and the
estimated glomerular ﬁltration rate.3,4 These different
results are most likely due to a lack of understanding of the
complex interaction between the different types of renal
diseases, their speciﬁc pathophysiology, and the complex
magnetic resonance (MR) signal generation. The choice of
shorter echo times in our study is surely not a relevant factor
explaining the differences between our ﬁndings and the
ﬁndings of other research groups. In contrast, the use of 3T
MR mandates the use of shorter echo times to yield reliable
image quality even with the longest echo time used.5 In
addition, similar echo times as in our study have also been
used by the group of Prasad et al., who pioneered the ﬁeld of
renal BOLD-MRI. Much more interesting than these
technical details are the implications of our study that have
been addressed by the authors of these letters. We concur that
our study does not imply that BOLD-MRI of the kidneys
should not be done. The main conclusion of our study was
that ‘broad application of renal BOLD MRI seems not
suitable’.3 The use of BOLD imaging in dedicated patient
groups should not be discouraged. In contrast, further studies
in patient groups with similar pathophysiological changes or
intraindividual studies are warranted. Under these premises
the inﬂuence of altered microvascular density or of the red
blood cell count and altered medications could be better
controlled. Novel approaches for image analysis of the
parametric R2* maps, such as the suggested region-
of-interest–based histogram plot, might further provide better
insights into pathology.
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Drug use and nephrotoxicity in
the intensive care unit: are we
under-dosing antimicrobials in
patients with acute kidney injury
with the need of extended
dialysis?
To the Editor: An important aspect that we would like to
raise, in addition to what Dr Perazella described as drug dose
adjustment1 in a recent review in this journal, is the use of
antibiotics in extended dialysis (ED). With ED, patients with
acute kidney injury have a potentially supraphysiologic drug
clearance during ED procedures, and this may be detrimental
in patients for whom bactericidal concentrations of antibiotics
are needed. Therefore, when the antibiotic is given in relation to
ED may be as important as the dosing. This premise has been
demonstrated by Lorenzen et al.,2 who reported that ampicillin/
sulbactam given too early or late in relation to ED could result
in supra- or subtherapeutic concentrations. Also considered
should be the pharmacodynamic properties of the antimicrobial
in question. Antimicrobials require speciﬁc attention to their
pharmacodynamic activity, as drugs that are time-dependent
killers may require a different timing and dosing compared
with those that kill in a concentration-dependent manner.3
Taking these considerations into account may be difﬁcult
enough, but complexity is added by the intensive care unit
(ICU) environment, to which access is limited, and procedures
may interfere with drug and dialysis scheduling.
In addition, there is paucity in dosing information of several
antibiotics commonly used in the ICU in patients with ED. ED
pharmacokinetics has been conducted in very few drugs.4
We agree with Dr Perazella that dosing of medications in
critically ill patients with acute renal replacement therapy is
challenging, and that practitioners should seek best evidence
and adjust their recommendation of dialysis parameters and
timing to optimize the dosing of antimicrobials.
1. Perazella MA. Drug use and nephrotoxicity in the intensive care unit.
Kidney Int 2012; 81: 1172–1178.
2. Lorenzen JM, Broll M, Kaever V et al. Pharmacokinetics of ampicillin/
sulbactam in critically ill patients with acute kidney injury undergoing to
extended dialysis. Clin J Am Soc Nephrol 2012; 7: 385–389.
Kidney International (2012) 82, 934–937 935
l e t t e r to the ed i to r
3. Dager WE, King JH. Aminoglycosides in intermittent hemodialysis:
pharmacokinetics with individual dosing. Ann Pharmacother 2006; 40:
9–14.
4. Bogard KN, Peterson NT, Plumb TJ et al. Antibiotic dosing during sustained
low-efficiency dialysis: special considerations in adult critically ill patients.
Crit Care Med 2011; 39: 560–571.
Fidel Barrantes1 and Timothy A. Horwedel2
1Renal Medicine Associates, Kidney Transplant Program, Presbyterian
Hospital, Albuquerque, New Mexico, USA and 2Barnes-Jewish Hospital,
St Louis, Missouri, USA
Correspondence: Fider Barrantes, Renal Medicine Associates, 201 Cedar
St SE, Suite 800, Kidney Transplant Program, Presbyterian Hospital,
Albuquerque, New Mexico 87106, USA. E-mail: Barrantes@renalmed.com
Kidney International (2012) 82, 935–936; doi:10.1038/ki.2012.285
Drug use in the intensive care unit
To the Editor: Drug use in the intensive care unit poses the
increased risk of nephrotoxicity. In this clinical setting two
typical errors should be avoided, namely overdosage and
underdosage—mainly of the anti-infective drugs. In his
valuable review on this topic, Mark A. Perazella suggested
adjusting the dose to the patient’s kidney function by using
the measured creatinine clearance (CrCl):1 ‘Maintenance
dose¼ standard dose (patient’s CrCl/normal CrCl), or Main-
tenance dosing interval¼ standard dosing interval (normal
CrCl/patient’s CrCl)’. However, the adjusted dose is not equal
to that clearance ratio. This has been shown by Luzius Dettli
using his classical two-step approach:2 The pharmacokinetic
parameters depend on kidney function according to a linear
function, and the dose must be adjusted to the pharmaco-
kinetic parameters in direct proportion to that change. With
greater drug clearance, the intercept of this linear function is
lower and the slope is higher, or the elimination half-life in
patients with failing kidney function (T1/2fail) differs from the
half-life value in normal individuals (T1/2norm). Bringing both
steps into one equation yields the following solution:
Dose
Interval
¼ Dose
Interval
 
norm
 1 1 T1=2norm
T1=2fail
 
 1 eGFRpatient
eGFRnorm
  
In addition, and as proposed in the Kidney Disease:
Improving Global Outcomes update, the creatinine clearance
could better be replaced by any of the common estimates of the
glomerular ﬁltration rate, such as the Cockcroft & Gault
equation, the Modiﬁcation of Diet in Renal Disease equation, or
the Chronic Kidney Disease Epidemiology Collaboration
formula.3 All three GFR estimates are based on simple serum
creatinine measurements.
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The Author Replies: Two letters to the editor raise
important issues about drug dosing and extracorporeal drug
clearance in intensive care unit patients.1,2 Critically ill
patients often suffer from acute kidney injury (AKI) and
multi-organ failure; they are the most complicated group for
whom nephrologists must provide care.3 By the nature of
their acute and chronic disease processes, they require
numerous pharmaceutical agents. Calculating the appropriate
dose is challenging and fraught with difﬁculty, as most
pharmacokinetic parameters are disrupted in critically ill
patients with AKI, especially when there is coexistent liver
injury. Changes in volume of distribution and altered drug
metabolism can lead to either lack of efﬁcacy or overt toxicity.
In addition, renal drug excretion is frequently abnormal,
difﬁcult to predict, quite dynamic, and further altered when
renal replacement therapy is added to the mix.
Dr Keller astutely points out the limitations of creatinine
clearance and its use as a ratio to determine drug dose
adjustments. I concede this point, but emphasize that my
intent was to bring the reader’s attention to the need for dose
adjustment in these patients because of their underlying
pharmacokinetic disturbances.3 All glomerular ﬁltration rate
(GFR) estimates in critically ill patients with AKI and/or
multi-organ failure perform poorly, thereby limiting their
utility in accurately dosing drugs. The Kidney Disease:
Improving Global Outcomes drug dosing recommendations,
which were published after my paper was written, are very
helpful.4 However, these formulas often signiﬁcantly over-
estimate GFR, and the GFR ranges utilized for drug dose
adjustment are anything but granular (o10, 10–50, 450).
Many of these problems would disappear if we could simply
measure drug concentrations. Until this is available for all
drugs, the goal of my drug-dosing guides was to familiarize
the reader with pharmacokinetic concepts and provide a
simple approach to dose adjustment (loading vs. maintenance
dose). Most importantly, I emphasize the need for a col-
laborative working relationship between clinical pharmacists
and critical-care nephrologists.
Barrantes and Horwedel appropriately note that attentive
care must be undertaken when dosing antibiotics in patients
on extended dialysis (ED). While pharmacokinetic drug
studies are limited for most continuous renal replacement
therapy modalities, ED is an even more understudied area,
although it has received recent interest.5 As the authors point
out, drug efﬁcacy and toxicity are related not only to the dose
administered, but also to the timing of the dose in relation
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